

May 14, 2009



ASCO Snapshot: Breast Cancer

Event: American Society of Clinical Oncology, May 29—June 2,



Market Leaders

Roche (OTC:RHHBY): Avastin, Herceptin, Tarceva, Xeloda: 2008 Sales USD 4498m, 4399m, 1050m, 1046m

[Genentech's Avastin should show durable effect on PFS in RIBBON-1 trial for widespread use, physicians say \(Pharmawire\)](#)
[Roche and Genentech's Avastin may see decline in use for metastatic breast cancer due to toxicity profile and pricing, physicians speculate \(Pharmawire\)](#)

[Genentech's AVADO trial faces "tough call" in showing overall survival benefit, physicians say \(Pharmawire\)](#)

Sanofi Aventis (NYSE:SNY): Taxotere: 2008 Sales USD 2697m

[Sanofi Aventis' Taxotere patent lawsuit leaves attorneys perplexed on noncompliance with 'offer of confidential access' contention - analysis \(Pharmawire\)](#)

AstraZeneca (NYSE:AZN): Arimidex, Zoladex: 2008 Sales USD 1857m, 1138m

Eli Lilly (NYSE:LLY): Gemzar, Alimta: 2008 Sales USD 1720m, 1155m

[Patents on gene-based diagnostic tests become increasingly vulnerable - analysis \(Pharmawire\)](#)

[Eli Lilly's Alimta patent challenge could protract as far as patent expiry in 2016; Teva's seeks to invalidate extension term - attorneys \(Pharmawire\)](#)



Unpartnered Targets in Development

Apthera (private): NeuVax

[Apthera Announces Phase III and Commercial Drug Formulation for NeuVax](#)

Nektar Therapeutics (NASDAQ:NKTR): NKTR-102: market cap USD 489m

[Nektar could acquire complementary technology, likely to partner compound this year, says CEO \(Pharmawire\)](#)

Peregrine Pharmaceuticals (NASDAQ:PPHM): bavituximab: cash USD 7m, cash burn 7 months

[Peregrine Pharmaceuticals completes enrollment in Phase II trial of bavituximab plus docetaxel in breast cancer](#)

[Peregrine Pharmaceuticals seeks partner for brain cancer drug Cotara, oncology compound bavituximab; Schering Plough tops list, CEO says \(Pharmawire\)](#)

Curagen (NASDAQ:CRGN): CR011-vcMMAE: market cap USD 56m

[CuraGen seeks partner or sale for non-core inflammatory compound, spokesperson says; analysts skeptical about drug's chances \(Pharmawire\)](#)

Generex Biotechnology (NASDAQ:GNBT): AE37 vaccine: market cap USD 51m

[Generex Biotechnology Announces Treatment of First Patient with its Novel Immunotherapeutic Vaccine](#)

Incyte (NASDAQ:INCY): INCB7839: market cap USD 273m: cash USD 151m, cash burn 15 months

[Data Presented at the 30th San Antonio Breast Cancer Symposium Supports Further Development of INCB7839 as a New Oral Treatment for Breast Cancer](#)

Medigene AG (FRA:MDG): EndoTAG-1: market cap EUR 152m: cash EUR 15m, cash burn 4 months

[Medigene wants to wait for release of EndoTAG-1 final results before agreeing partnership or M&A deal - spokesperson \(Pharmawire\)](#)